Category: Anticancer
Each vial contains:-
Each vial contains: Irinotecan ………………….. 40mg/2ml, 100mg/5ml
Specifications
Irinotecan injection is supplied as a sterile, pale yellow, clear, aqueous solution. The pH of the solution is in between 3.0 to 3.8.
| Composition : | Each vial contains:
Irinotecan ………………….. 40mg/2ml, 100mg/5ml Water for Injection ……. q.s. | | Indications : | It is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.
It is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.
. | | Contraindications : | It is contraindicated in patients with a known hypersensitivity to the drug or its excipients.
| | Pharmacological action: | Irinotecan is a derivative of camptothecin. It interact specifically with the enzyme topoisomerase I which relieves torsional strain in DNA by inducing reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I-DNA complex and prevent religation of these single-strand breaks.
| | Adverse Effects : | : Abdominal discomfort, diarrhoea, Leukopenia, neutropenia, haemorrhage, body pain, insomania, dizziness, anaemia vomiting, nausea | | Dosage : | Irinotecam should be administered as an intravenous infusion over 90 minutes for both the weekly and once-every-3-week dosage schedules.
Weekly dose schedule: The usual starting dose is 125 mg/m2. Subsequent doses may be adjusted to as high as 150 mg/m2.
Once every three week schedule: starting dose is 350 mg.m2 | | Storage: | 2-80C
| | Purity : | Not less than 99%. | |
 | |  |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
